Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicenter, 3-period Incomplete Block, Multidose Crossover Study to Determine the Effect on Lung Function of Indacaterol (150 and 300 μg o.d.) in Patients With Moderate to Severe COPD, Using Tiotropium (18 μg o.d.) as an Active Control
Brief Summary: The study compared the 24-hour spirometry profile of indacaterol with that of placebo and with tiotropium as an active control in patients with chronic obstructive pulmonary disease.


Options:
A: Arm Label: Olodaterol (BI 1744) Low; Type: EXPERIMENTAL; Interventions: Drug: Olodaterol (BI 1744) | Arm Label: Olodaterol (BI 1744) High; Type: EXPERIMENTAL; Interventions: Drug: Olodaterol (BI 1744) | Arm Label: Formoterol 12mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Olodaterol (BI 1744); Assigned to Arm(s): Olodaterol (BI 1744) Low | Intervention Type: DRUG; Name: Olodaterol (BI 1744); Assigned to Arm(s): Olodaterol (BI 1744) High | Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): Formoterol 12mcg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Sequence 1: Placebo,Tiotropium, Indacaterol 150 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Tiotropium, Drug: Placebo | Arm Label: Sequence 2: Indacaterol 300 μg, Indacaterol 150 μg, Tiotropium; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Tiotropium | Arm Label: Sequence 3: Indacaterol 150 μg, Indacaterol 300 μg, Placebo; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Placebo | Arm Label: Sequence 4: Tiotropium, Placebo, Indacaterol 300 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Tiotropium, Drug: Placebo | Intervention Type: DRUG; Name: Indacaterol; Assigned to Arm(s): Sequence 1: Placebo,Tiotropium, Indacaterol 150 μg, Sequence 2: Indacaterol 300 μg, Indacaterol 150 μg, Tiotropium, Sequence 3: Indacaterol 150 μg, Indacaterol 300 μg, Placebo, Sequence 4: Tiotropium, Placebo, Indacaterol 300 μg | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Sequence 1: Placebo,Tiotropium, Indacaterol 150 μg, Sequence 2: Indacaterol 300 μg, Indacaterol 150 μg, Tiotropium, Sequence 4: Tiotropium, Placebo, Indacaterol 300 μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 1: Placebo,Tiotropium, Indacaterol 150 μg, Sequence 3: Indacaterol 150 μg, Indacaterol 300 μg, Placebo, Sequence 4: Tiotropium, Placebo, Indacaterol 300 μg
C: Arm Label: Indacaterol first; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Tiotropium | Arm Label: Tiotropium first; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Tiotropium | Intervention Type: DRUG; Name: Indacaterol; Assigned to Arm(s): Indacaterol first, Tiotropium first | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Indacaterol first, Tiotropium first
D: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: indacaterol and glycopyrronium (QVA149), Drug: Placebo to fluticasone/salmeterol | Arm Label: fluticasone/salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone/salmeterol, Drug: Placebo to indacaterol and glycopyrronium (QVA149) | Intervention Type: DRUG; Name: indacaterol and glycopyrronium (QVA149); Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Placebo to fluticasone/salmeterol; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: fluticasone/salmeterol; Assigned to Arm(s): fluticasone/salmeterol | Intervention Type: DRUG; Name: Placebo to indacaterol and glycopyrronium (QVA149); Assigned to Arm(s): fluticasone/salmeterol

Answer: B